AstraZeneca Puts $2 Billion Into Summit

$2 billion will go from AstraZeneca to Summit Therapeutics for newly issued shares, disclosed 28 September 2026, AstraZeneca said. As a primary raise, the cash goes straight to Summit. AstraZeneca calls it a strategic investment. My read: exposure without a takeover — risking cash now to keep options open later.